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Abstract
Background: Neuroinflammatory responses are triggered by diverse ethiologies and can provide
either beneficial or harmful results. Microglial cells are the major cell type involved in
neuroinflammation, releasing several mediators, which contribute to the neuronal demise in several
diseases including cerebral ischemia and neurodegenerative disorders. Attenuation of microglial
activation has been shown to confer protection against different types of brain injury. Recent
evidence suggests that resveratrol has anti-inflammatory and potent antioxidant properties. It has
been also shown that resveratrol is a potent inhibitor of cyclooxygenase (COX)-1 activity. Previous
findings have demonstrated that this compound is able to reduce neuronal injury in different
models, both in vitro and in vivo. The aim of this study was to examine whether resveratrol is able
to reduce prostaglandin E2  (PGE2) and 8-iso-prostaglandin F2α  (8-iso-PGF2α) production by
lipopolysaccharide (LPS)-activated primary rat microglia.
Methods: Primary microglial cell cultures were prepared from cerebral cortices of neonatal rats.
Microglial cells were stimulated with 10 ng/ml of LPS in the presence or absence of different
concentrations of resveratrol (1–50 µM). After 24 h incubation, culture media were collected to
measure the production of PGE2 and 8-iso-PGF2α using enzyme immunoassays. Protein levels of
COX-1, COX-2 and microsomal prostaglandin E synthase-1 (mPGES-1) were studied by Western
blotting after 24 h of incubation with LPS. Expression of mPGES-1 at the mRNA level was
investigated using reverse transcription-polymerase chain reaction (RT-PCR) analysis.
Results: Our results indicate that resveratrol potently reduced LPS-induced PGE2 synthesis and
the formation of 8-iso-PGF2α, a measure of free radical production. Interestingly, resveratrol dose-
dependently reduced the expression (mRNA and protein) of mPGES-1, which is a key enzyme
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responsible for the synthesis of PGE2 by activated microglia, whereas resveratrol did not affect the
expression of COX-2. Resveratrol is therefore the first known inhibitor which specifically prevents
mPGES-1 expression without affecting COX-2 levels. Another important observation of the
present study is that other COX-1 selective inhibitors (SC-560 and Valeroyl Salicylate) potently
reduced PGE2 and 8-iso-PGF2α production by LPS-activated microglia.
Conclusion: These findings suggest that the naturally occurring polyphenol resveratrol is able to
reduce microglial activation, an effect that might help to explain its neuroprotective effects in
several in vivo models of brain injury.
Background
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a polyphe-
nolic compound present in relatively large amounts in
grapes and red wine. In smaller quantities, resveratrol is
also present in almost 70 plant species, where it has been
found to act as an anti-fungicide and confer disease resist-
ance in the plant kingdom [1]. Recently, this natural com-
pound has received a great deal of attention due to its
ability to serve as a potent antioxidant [2]. In addition,
resveratrol has been proven to possess anti-inflammatory,
immunomodulatory, chemopreventive, neuroprotective,
and cardioprotective properties [3-10].
One of the most interesting properties of resveratrol is its
ability to confer potent neuroprotection in several models
of brain injury, both in vitro [10-12] and in vivo
[7,8,13,14]. Resveratrol readily crosses the intact blood-
brain barrier as demonstrated in previous studies [7,15].
There is much evidence from recent studies, which indi-
cate that ischemic brain injury is potently reduced in res-
veratrol-treated animals. The first report suggesting that
cerebral infarction is significantly diminished by systemic
administration of resveratrol comes from Huang et al.
[13], using an in vivo model of focal cerebral ischemia in
rats. In another study, resveratrol increased the number of
CA1 hippocampal neurons surviving a global cerebral
ischemic insult [7]. Resveratrol not only reduced neuronal
death but also reduced the number of reactive astrocytes
and activated microglial cells [7]. The free radical scaveng-
ing ability seems to underlie the efficacy of resveratrol
against neuronal demise in cerebral ischemia, as sug-
gested in a recent study [16].
In order to explain at the molecular level the mechanisms
responsible for resveratrol neuroprotection under
ischemic conditions, in vitro models involving neuronal
cultures as well as hippocampal slices subjected to oxy-
gen-glucose deprivation have been employed. Nitric
oxide-related toxicity to cultured hippocampal neurons
was dramatically inhibited by resveratrol through a mech-
anism that seems to be at least partially related to its anti-
oxidant effect [11]. Similarly, resveratrol attenuated cell
death in organotypic hippocampal slice cultures exposed
to oxygen-glucose deprivation through activation of the
phosphoinositide-3-kinase (PI3-K)/Akt pathway [17].
The neuroprotective effect of resveratrol is not only
restricted to cerebral ischemia. This natural compound
also reduced oxidative stress and lesion volume in a
model of traumatic brain injury [18] and spinal cord
injury [19,20] in rats. Furthermore, resveratrol protected
against excitotoxicity induced by kainic acid [8], and oxi-
dative stress and behavioral changes in a rat model of
Huntington's disease [21]. In addition, it has been
recently demonstrated that resveratrol promotes intracel-
lular degradation of amyloid β peptide via a mechanism
that involves the proteasome [22].
Although mounting evidence convincingly demonstrates
the potential of resveratrol to provide significant protec-
tion against different types of brain injury, the exact
molecular mechanisms responsible for these beneficial
effects are not fully elucidated. Its antioxidant ability
alone can not give an explanation to the wide array of
pharmacological properties of this compound.
Microglial cells are important protagonists in the cascade
of events leading to tissue injury following neurodegener-
ation and other types of cerebral damage [23-28]. Very
few studies have investigated the effects of resveratrol on
microglial activation during neuroinflammation. In an
earlier study, resveratrol was found to produce a potent
suppressive effect on tumor necrosis factor α (TNFα) and
nitric oxide production induced by lipopolysaccharide
(LPS) in the mouse microglial cell line N9 [29]. These
effects are mediated through inhibition of nuclear factor
κB (NF-κB) activation and p38 MAPK phosphorylation
[29].
Based on these previous reports, the present study was
undertaken to investigate the effects of resveratrol on neu-
roinflammatory events associated to the production of
prostaglandin E2 and reactive oxygen species (ROS) in
activated primary microglial cells. Our findings indicate
for the first time that resveratrol is a potent inhibitor of
PGE2 production in microglia through a mechanism that
involves reduction in the expression of the key enzymeJournal of Neuroinflammation 2007, 4:25 http://www.jneuroinflammation.com/content/4/1/25
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involved in PGE2 formation, namely, microsomal pros-
taglandin E synthase-1 (mPGES-1). Direct inhibitory
effects of resveratrol on cyclooxygenase activity as well as
reduction in 8-isoprostane formation are other beneficial
effects that contribute to the potent attenuation of micro-
glial activation, and possibly to the neuroprotective effi-
cacy of this natural compound in different models of
brain injury.
Methods
Reagents and Antibodies
Trans-resveratrol, Trolox C, α-tocopherol, and LPS (from
Salmonella typhimurium) were obtained from Sigma-
Aldrich (Taufkirchen, Germany). LPS was resuspended in
sterile phosphate buffered saline (PBS; Cell Concepts,
Umkirch, Germany) as 5 mg/ml stock, and was used at a
final concentration of 10 ng/ml in the culture. The COX-
1 inhibitors SC-560 and Valeroyl salicylate (VAS) were
obtained from Cayman Chemical Co. (Ann Arbor, USA).
Resveratrol, Trolox C, and α-tocopherol were dissolved in
absolute ethanol. SC-560 and VAS were dissolved in
DMSO and water, respectively. Solvent concentration in
the culture media was maintained at less than 0.1%. All
agents, used at the given concentrations, do not affect the
viability of the cells as observed through a luminescent kit
(Promega, Madison, WI, USA), which measures metabolic
ATP levels (data not shown). Antibodies against COX-1
(M-20) and COX-2 (M-19) were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Rabbit polyclonal anti-
body against mPGES-1 was obtained from Cayman
Chemical Co. (Ann Arbor, MI, USA), while the antibody
against actin was from Sigma (Saint Louis, MO, USA).
Primary rat microglial cell culture
Primary mixed glial cell cultures were established from
cerebral cortices of one-day neonatal Sprague-Dawley rats
as described in details in our previous reports [30-34].
Briefly, forebrains were minced and gently dissociated by
repeated pipetting in PBS and filtered through a 70-µm
cell strainer (Falcon). Cells were collected by centrifuga-
tion (1000 rpm, 10 min), resuspended in Dulbecco's
modified Eagle's medium (DMEM) containing 10% fetal
calf serum (Biochrom AG, Berlin, Germany) and antibiot-
ics (40 U/ml penicillin and 40 µg/ml streptomycin, both
from PAA Laboratories, Linz, Austria), and cultured on
10-cm cell culture dishes (5 × 105 cells/plate, Falcon) in
5% CO2 at 37°C. Medium was prepared taking extreme
care to avoid LPS contamination [35]. Floating microglia
were harvested every week (between 2–7 week) and re-
seeded into 75 cm2 culture flask (for RNA extraction and
Western blots) or 24-well plates (for 8-isoprostane and
PGE2 estimation) to give pure microglial cultures. The fol-
lowing day, cultures were washed to remove non-adher-
ent cells, and fresh medium was added. The purity of the
microglial culture was >98% as previously determined by
immunofluorescence and cytochemical analysis [35].
Prostaglandin E2 (PGE2) Enzyme Immunoassay
Supernatants were harvested, centrifuged at 10,000 × g for
10 min and levels of PGE2 in the media were measured by
enzyme immunoassay (EIA) (Assay Designs Inc., Ann
Arbor, MI, USA; distributed by Biotrend, Cologne, Ger-
many) according to the manufacturer's instructions.
Standards from 39 to 2500 pg/ml were used. The sensitiv-
ity of this assay is 36.2 pg/ml.
Cyclooxygenase Activity Assay
To determine any direct inhibitory effect of resveratrol on
COX-1 and COX-2 enzymatic activity, an arachidonic acid
assay was performed as described [36,37]. Briefly, primary
rat microglial cells were plated in 24-well cell culture
plates, and pre-incubated with LPS (10 ng/ml) for 24 h.
Medium was then removed, and cells washed in serum-
free medium. Resveratrol (5–50 µM) was added, and after
15 min pre-stimulation, 15 µM arachidonic acid was sup-
plemented for another 15 min. Supernatants were then
used for determination of PGE2 [36]. We also investigated
the effects of resveratrol on microglial COX-1 enzymatic
activity. Under unstimulated conditions, primary micro-
glial cells only express the COX-1 isoform [34]. Thus, the
COX-1 activity assay was conducted exactly as mentioned
before without pre-incubation with LPS.
RNA Isolation and Reverse Transcription-Polymerase 
Chain Reaction (RT-PCR)
Total RNA was extracted using the guanidine isothiocy-
anate method according to Chomczynski and Sacchi [38].
For RT-PCR, 2 µg of total RNA was reverse transcribed
using Moloney Murine Leukemia Virus (M-MLV) reverse
transcriptase (Promega, Mannheim, Germany), RNase
Inhibitor rRNasin® (Promega), dNTP master mix (Invitek,
Berlin, Germany) and random hexamer primers
(Promega). PCR was carried out using Taq DNA polymer-
ase (Promega), dNTP master mix (Invitek, Berlin, Ger-
many) and the following primers: rat microsomal
prostaglandin E synthase-1, mPGES-1 (forward: 5'-ATG
ACT TCC CTG GGT TTG GTG ATG GAG -3', reverse: 5'-
ACA GAT GGT GGG CCA CTT CCC AGA -3', annealing
temperature 65°C, 35 cycles, amplicon size: 459 bp).
Primers for rat COX-2 were as follows: forward, 5'-TGC
GAT GCT CTT CCG AGC TGT GCT-3' and reverse, 5'- TCA
GGA AGT TCC TTA TTT CCT TTC-3', annealing tempera-
ture 55°C, 35 cycles, amplicon size: 479 bp). Primers used
for amplifying a fragment of 426 bp from rat COX-1
mRNA were: forward, 5'-CGG CCT CGA CCA CTA CCA
ATG -3' and reverse, 5'- TGC GGG GCG GGA ATG AAC T-
3', annealing temperature 60°C, 30 cycles. Equal equili-
bration was determined using rat β-actin primers (for-
ward: 5'- ATG GAT GAC GAT ATC GCT -3', reverse: 5'-Journal of Neuroinflammation 2007, 4:25 http://www.jneuroinflammation.com/content/4/1/25
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ATG AGG TAG TCT GTC AGG T -3', 48°C, 30 cycles, prod-
uct length: 569 bp) or primers for S12 from rat (forward:
5'- ACG TCA ACA CTG CTC TAC A -3', reverse: 5'- CTT
TGC CAT AGT CCT TAA C -3', 56°C, 30 cycles, product
length: 312 bp). PCR products were separated electropho-
retically on a 2% agarose gel. Potential contamination by
genomic DNA was controlled by omitting reverse tran-
scriptase and using primers for the housekeeping genes
(β-actin or S12) in the subsequent PCR amplification.
Only RNA samples showing no bands after this procedure
were used for further investigation. Primers were designed
using the Primer3 software developed by the Whitehead
Institute for Biomedical Research [39], and synthesized
through an in-house facility (Dr. Gabor Igloi, Institute for
Biology III, Freiburg, Germany). PCR analysis was per-
formed after 4 h of stimulation with LPS.
Western blot analysis
For COX-1, COX-2 and mPGES-1 immunoblotting,
microglial cells were left untreated or treated with LPS (10
ng/ml) in the presence or absence of resveratrol (1–50
µM) for 24 h. Cells were washed with phosphate buffered
saline (PBS) and lysed in 1.3x SDS (sodium dodecyl sul-
fate)-containing sample buffer without DTT or
bromophenol blue containing 100 µM orthovanadate
[40]. Lysates were homogenized by repeated passage
through a 26-gauge needle. Protein contents were meas-
ured using the bicinchoninic acid method (BCA protein
determination kit from Pierce, distributed by KFC Chemi-
kalien, Munich, Germany) according to the manufac-
turer's instructions. Bovine serum albumin (BSA, Sigma)
was used as a standard. Before electrophoresis,
bromophenol blue and DTT (final concentration, 10
mM) were added to the samples. For Western blotting, 60
µg of total protein from each sample were subjected to
SDS-PAGE (polyacrylamide gel electrophoresis) under
reducing conditions. Proteins were then transferred onto
a polyvinylidene fluoride (PVDF) membrane (Millipore,
Bedford, MA, USA) by semi-dry blotting. The membrane
was blocked overnight at 4°C using Rotiblock (Roth, Karl-
sruhe, Germany) and for another hour at room tempera-
ture before incubation with the primary antibody.
Primary antibodies were goat anti-COX-2, goat anti-COX-
1 and rabbit anti-mPGES-1. Primary antibodies were
diluted 1:500 in Tris-buffered saline (TBS) containing
0.1% Tween 20 (TBST) and 1% bovine serum albumin
(BSA, Sigma). Membranes were incubated with the corre-
sponding primary antibody for 2 h at room temperature.
After extensive washing (three times for 15 min each in
TBST), proteins were detected with horseradish peroxi-
dase-coupled rabbit anti-goat IgG (Santa Cruz, 1:100,000
dilution) or goat anti-rabbit IgG (Amersham, 1:25,000
dilution) using chemiluminescence (ECL) reagents
(Amersham Pharmacia Biotech, Freiburg, Germany).
Quantification of the Western blots was performed using
ScanPack 3.0 software (Biometra, Göttingen, Germany).
Equal protein loading and transfer were assessed by sub-
jection of each sample to a Western blot for actin (rabbit
anti-actin IgG, diluted 1:5000). All western blot experi-
ments were carried out at least three times.
Determination of 8-iso-prostaglandin F2α (8-iso-PGF2α)
8-isoprostanes are formed in response to free radical
attack on arachidonic acid on membrane phospholipids
and are considered as a reliable and highly sensitive meas-
ure of free radical formation [41]. Microglial cells were
pre-treated for 30 min with different concentrations of
resveratrol, Trolox C, α-tocopherol, SC-560, or VAS (see
Results and Figures). After 30 min pre-stimulation, cells
were added 10 ng/ml LPS for 24 h. Control experiments
consisted of cells treated only with the solvent of each
compound without LPS. Supernatants were harvested and
the levels of 8-iso-PGF2α (IUPAC nomenclature: 15-F2t-
IsoP) were measured by an enzyme immunoassay accord-
ing to the manufacturer's instructions (Cayman Chemi-
cals, Ann Arbor, MI, USA). The standards were used in the
range of 3.9 to 500 pg/ml (detection limit of 5 pg/ml).
Data analysis
Data from at least 3 experiments were used for data anal-
ysis. Original data were converted into %-values of LPS
control and mean ± S.E.M. were calculated. Values were
compared using t-test (two groups) or one-way ANOVA
with post-hoc Student-Newman-Keuls test (multiple com-
parisons).
Results
In our initial experiments, we investigated the effects of
resveratrol on LPS-induced PGE2 production in microglia.
As shown in Fig. 1A, resveratrol potently diminished PGE2
synthesis starting at 1 µM and showing a dose-dependent
inhibitory effect between 1 and 10 µM. The higher doses
of resveratrol tested in this study did not further decrease
PGE2 formation, maintaining PGE2 at basal levels (not dif-
ferent from unstimulated control cells). Since resveratrol
is a potent antioxidant compound, we decided to examine
if other antioxidants were also able to modify PGE2 pro-
duction by activated microglia. In contrast to resveratrol,
the antioxidants α-tocopherol and its synthetic analogue
Trolox C only slightly reduced PGE2 biosynthesis at rela-
tively high doses (100 and 250 µM respectively; Fig. 1B).
These antioxidant compounds were unable to reduce
PGE2 formation when added to the microglial cultures at
lower doses (data not shown).
These findings prompted us to investigate the ability of
resveratrol to reduce COX enzymatic activity in activated
microglia. Results from this experiment are shown in Fig.
2. Significant inhibition of COX-1 activity was observed
when microglial cells were pre-incubated for 30 min withJournal of Neuroinflammation 2007, 4:25 http://www.jneuroinflammation.com/content/4/1/25
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25 and 50 µM of resveratrol (Fig. 2A). The effect of resver-
atrol on total COX activity (COX-1 + COX-2) was also
investigated. In this in vitro assay, cells were pre-incubated
with LPS for 24 h before resveratrol was added for 30 min,
and PGE2 levels were measured in the supernatant. The
addition of resveratrol produced a significant inhibition
of COX activity starting at 10 µM and showing a 50% inhi-
bition with the highest dose of 50 µM (Fig. 2B).
Since there are significant changes in gene expression in
LPS-activated microglia, including a dramatic upregula-
tion of the PGE2  synthesizing enzymes COX-2 and
mPGES-1 [31,34,42], we decided to investigate the effects
of resveratrol on the expression of these key enzymes
responsible for PGE2 production in LPS-stimulated micro-
glia, at both the mRNA and protein levels. RT-PCR analy-
sis showed that control microglial cells do not express
COX-2 or mPGES-1 mRNA under control conditions, but
the expression of these enzymes is dramatically induced
by addition of LPS to the cultures (Fig. 3A). Of great inter-
est is our finding that resveratrol produced a significant
reduction in the expression of mPGES-1 mRNA, without
modifying COX-2 mRNA expression (Figs. 3A and 3B).
Similar results were observed when investigating the
effects of resveratrol on mPGES-1 protein levels as
assessed by Western blotting (Fig. 4A). It is important to
emphasize that resveratrol did not modified basal COX-1
or LPS-induced COX-2 expression in microglia. A densit-
Cyclooxygenase enzymatic activity in microglial cells is inhib- ited by resveratrol treatment Figure 2
Cyclooxygenase enzymatic activity in microglial cells is inhib-
ited by resveratrol treatment. For the COX-1 activity assay 
(A), cells were left untreated and different concentrations of 
resveratrol were added for 15 min. After this incubation 
time, 15 µM of arachidonic acid was added and PGE2 meas-
ured after 15 min. For total COX activity assay (COX-1 + 
COX-2), cells were either left untreated or were stimulated 
with LPS (10 ng/ml) for 24 h. After removal of medium, cells 
were treated with different concentrations of resveratrol for 
30 min in absence or presence of 15 µM of arachidonic acid. 
PGE2 in the supernatants was measured by an enzyme immu-
noassay as described in Materials and Methods. Data are 
expressed as mean ± S.E.M. Statistical analysis was performed 
using one-way ANOVA followed by the Student-Newman-
Keuls post-hoc test. *p < 0.05 and **p < 0.01 with respect to 
untreated control (without resveratrol).
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A: Resveratrol dose-dependently inhibits LPS-induced PGE2 
production in primary rat microglial cells. B: Effects of 
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between the treatments. *p < 0.05, **p < 0.01 and ***p < 
0.001 with respect to LPS control (One-way ANOVA fol-
lowed by the Student-Newman-Keuls post-hoc test).
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ometric analysis of protein levels of mPGES-1 and COX-2,
and the effects of resveratrol are presented in Fig. 4B.
Since resveratrol has been proven to have potent antioxi-
dant properties, we aimed to determine the efficacy of this
compound in reducing free radical production by acti-
vated microglia. LPS produced a very significant increase
in the formation of 8-iso-PGF2α, a very sensitive marker of
cellular free radical generation, as assessed by enzyme
immunoassay (Fig. 5). More importantly, resveratrol
potently reduced LPS-mediated formation of ROS, an
effect that was seen at very low doses (starting at 1 µM).
This reduction in 8-iso-PGF2α by resveratrol showed a con-
centration-dependent response between 1 and 10 µM
(Fig. 5A), an effect also seen in our first experiment evalu-
ating PGE2 levels (Fig. 1A). We then tested the ability of
two well-known antioxidants, Trolox C and α-tocopherol,
to reduce free radical formation in LPS-activated micro-
glia. These antioxidants significantly reduced 8-iso-PGF2α
as well, but not as potent as resveratrol (Fig. 5B).
The ability of resveratrol to inhibit the peroxidase activity
of COX-1 is a well-known pharmacological effect of this
compound [43,44]. It was then very important to investi-
gate the ability of other COX-1 inhibitors to reduce PGE2
and 8-iso-PGF2α production in microglia activated with
LPS. Interestingly, two structurally different highly selec-
tive COX-1 inhibitors (SC-560 and VAS) potently reduced
A: Immunoblot analysis of protein levels of COX-1, COX-2,  mPGES-1, and actin in LPS-activated microglia treated with  different concentrations of resveratrol (1–50 µM) Figure 4
A: Immunoblot analysis of protein levels of COX-1, COX-2, 
mPGES-1, and actin in LPS-activated microglia treated with 
different concentrations of resveratrol (1–50 µM). Microglial 
protein extracts were prepared after 24 h of incubation with 
LPS, and subjected to SDS-PAGE followed by immunoblot 
analysis using specific antibodies for each protein. B: Quanti-
tative densitometric analysis of mPGES-1 and COX-2 protein 
expression normalized to actin loading control. Resveratrol 
potently reduced mPGES-1 protein expression induced by 
LPS. *p < 0.05 and **p < 0.01 with respect to untreated LPS 
control. Bars represent mean ± S.E.M. of 4 independent 
experiments.
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A: Representative photomicrographs showing RT-PCR prod-
ucts of COX-1, COX-2, mPGES-1, and β-actin mRNAs. 
Microglial cells were treated with LPS (10 ng/ml) in the 
absence or presence of different concentrations of resvera-
trol. The mRNA expression levels were tested for each con-
dition. There is a constitutive COX-1 mRNA expression that 
is observed under all conditions. However, COX-2 and 
mPGES-1 are undetectable in untreated microglial cells, while 
their expression is dramatically increased in the presence of 
LPS. Resveratrol treatment significantly reduced mPGES-1, 
but not COX-2 expression. RT-PCR analysis was performed 
after 4 h of incubation with LPS. Resveratrol was added to 
the cultures 30 min before LPS. B: Semi-quantitative analysis 
of the effect of resveratrol on mPGES-1 expression. This 
analysis was done with results from 4 different RT-PCR 
experiments performed independently. Relative expression 
of rat β-actin was used for normalization. The amplicon size 
of the PCR product appears below the name of each tran-
script. *p < 0.05 and **p < 0.01 with respect to untreated 
LPS control.
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PGE2 production (Fig. 6A and 6C) and free radical forma-
tion (Fig. 6B and 6D) in activated microglia in a dose-
dependent manner.
Next, we examined the potential effects of SC-560 and
VAS on LPS-mediated mPGES-1 expression, which could
help to explain if the effects of resveratrol on the reduction
in mPGES-1 were mediated by a COX-1 mechanism. RT-
PCR analysis reveals that COX-1 inhibition by SC-560 or
VAS failed to reduce mPGES-1 expression in LPS-activated
primary microglia (Fig. 7A and 7B).
Since previous studies have shown the ability of antioxi-
dants to modify gene expression of pro-inflammatory
mediators in activated microglia [31,45], we studied the
effects of Trolox C on LPS-induced COX-2 and mPGES-1
expression. Trolox C slightly reduced mPGES-1 expres-
sion, although this effect did not reach statistical signifi-
cance, as found in the densitometric analysis of three
independent experiments (Fig. 7B). In another control
experiment, we investigated the effects of COX-1 inhibi-
tors and Trolox C on the expression of both COX iso-
zymes. No effect of these compounds was observed in our
in vitro model, as shown in Fig. 7. Furthermore, we also
investigated if other COX inhibitors might have an effect
on the expression of mPGES-1 by activated microglia.
These compounds included the non-selective COX inhib-
itors indomethacin and ibuprofen, as well as the highly
selective COX-2 inhibitor SC-58125. None of these com-
pounds modify the LPS-induced mPGES-1 expression
(data not shown).
Discussion
Scientific literature on natural compounds has been
recently accumulating an enormous amount of reports
describing the neuroprotective ability of natural polyphe-
nolic substances in different models of brain injury both
in vitro and in vivo. Resveratrol is one of the most promis-
ing compounds, considering recent evidence indicating its
potent ability to reduce cerebral damage after ischemia/
hypoxia [7,13,17], trauma [18], excitotoxicity [8], and
other conditions leading to neuronal demise [19,21].
It is widely accepted that neuroinflammation is a key
player in various pathological events associated with
brain injury. More specifically, microglial activation and
the subsequent release of pro-inflammatory cytokines,
ROS, and prostaglandins play a role of paramount impor-
tance in cerebral damage. Inhibition of COX-2 induction
and/or activity has been proven to reduce brain injury
after ischemia [46-50], excitotoxicity [47,51], and MPTP-
induced neurodegeneration [52-54]. The most important
mechanisms associated with the toxic effects of enhanced
COX activity during neuroinflammation include produc-
tion of PGE2 [55-59] and formation of free radicals lead-
ing to oxidative stress [34,37,60,61].
In the present study, we have found that resveratrol is a
potent inhibitor of PGE2 and free radical formation by
activated microglial cells. These findings add significant
information on the molecular mechanisms involved in
the neuroprotective effect of this compound. The ability
of resveratrol to reduce PGE2 production comes from the
modulation of multiple events in the COX/PGE2 pathway:
1) resveratrol is a potent inactivator of the peroxidase
reaction of COX-1 [43], and thus is considered a relatively
selective inhibitor of this isozyme; 2) resveratrol signifi-
cantly diminished LPS-induced expression of mPGES-1
(Figs. 3 and 4), the most important terminal synthase
responsible for PGE2 synthesis in activated microglia [42];
and 3) production of 8-iso-PGF2α, a reliable indicator of
free radical generation, is dramatically reduced by low
concentrations of resveratrol (Fig. 5).
A: Effect of resveratrol on 8-iso-prostaglandin F2α (8-iso- PGF2α) production in response to 10 ng/ml LPS Figure 5
A: Effect of resveratrol on 8-iso-prostaglandin F2α (8-iso-
PGF2α) production in response to 10 ng/ml LPS. 8-iso-PGF2α 
was determined in the culture medium 24 h following stimu-
lation of microglial cells with LPS alone, or in combination 
with resveratrol at the given concentrations. B: Moderate 
reduction in LPS-mediated 8-iso-PGF2α formation by the anti-
oxidants Trolox C and α-tocopherol. *p < 0.05, **p < 0.01 
and ***p < 0.001 with respect to LPS alone. For both panels, 
histograms represent mean ± S.E.M. of 4 independent exper-
iments. Statistical analysis was performed using one-way 
ANOVA followed by Student-Newman-Keuls post-hoc test.
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The relative contribution of each of these mechanisms to
the overall reduction in PGE2 by resveratrol is difficult to
address based on present data. However, some issues
deserve further discussion. The ability of resveratrol to
inhibit the peroxidase activity of COX-1 is a well-known
pharmacological effect of this compound [43,44]. COX-1
is constitutively expressed in microglia under resting con-
ditions, and its expression is not induced by LPS as shown
in Figs. 3A and 4A, and reported by us before [34]. How-
ever, according to present results, there is a significant
contribution of COX-1 to PGE2 formation by microglia
upon LPS challenge. This is supported by a previous study
performed in LPS-stimulated human adult microglial
cells, in which selective inhibition of COX-1 was also very
effective in reducing PGE2 production [62]. Results from
control experiments using other highly selective COX-1
inhibitors (SC-560 and VAS), in addition to resveratrol,
indicate that COX-1 isoform is not only important in LPS-
induced PGE2 synthesis, but it is also a key source of free
radicals in microglia. This is an unexpected observation,
and represents the first evidence that microglial COX-1
activity is a significant source of free radicals during neu-
roinflammation.
It has been previously shown that increased COX activity
is associated with oxidative damage following different
types of brain injury, including excitotoxicity [61,63,64],
ischemia [60,65,66], and traumatic brain injury [67]. Fur-
thermore, treatment with COX inhibitors has been proven
to significantly reduce IL-1β- and LPS-induced oxidative
damage in neuronal and microglial cells, respectively
[34,37].
The interesting pharmacological properties of resveratrol
in terms of inhibition of COX-1 and direct antioxidant
ability, may underlie the dramatic attenuation of PGE2
and free radical production by LPS-activated microglia. It
has long been known that free radicals directly increase
COX activity and conversely antioxidants reduce COX cat-
alytic activity [68-70]. Based on these reports, one may
speculate that maintenance of microglial redox status by
resveratrol contributes to the reduction in COX activity
and PGE2 production in these cells. This is further sup-
ported by our finding that other antioxidants (Trolox C
and α-tocopherol) are also able to reduce PGE2 formation
(Fig. 1B). Antioxidants have been shown to modulate
microglial activation [71-74]. In an earlier study, vitamin
Potent inhibition of LPS-induced PGE2 (A and C) and 8-iso-PGF2α formation (B and D) by two highly selective COX-1 inhibi- tors (SC-560 and VAS) Figure 6
Potent inhibition of LPS-induced PGE2 (A and C) and 8-iso-PGF2α formation (B and D) by two highly selective COX-1 inhibi-
tors (SC-560 and VAS). After 30 min pre-stimulation with the inhibitors, LPS (10 ng/mL) was added to the culture medium, and 
the amounts of PGE2 and 8-iso-PGF2α were determined using specific enzyme immunoassays after 24 h incubation with LPS. For 
all panels, histograms represent mean ± S.E.M. of 4 independent experiments. Statistical analysis was performed using one-way 
ANOVA followed by Student-Newman-Keuls post-hoc test. *p < 0.05, **p < 0.01 and ***p < 0.001 with respect to LPS control.
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E was found to attenuate nitric oxide production and the
induction of IL-1α and TNFα expression through suppres-
sion of signaling events necessary for microglial activation
[71]. Furthermore, inhibition of ROS generation in LPS-
activated microglia can reduce PGE2  production as
reported previously by Wang et al [73].
An important new observation of the present study is the
dramatic reduction in LPS-mediated expression of
mPGES-1 in cells treated with resveratrol (Figs. 3 and 4).
Based on very recent and convincing data, production of
PGE2  in microglia following LPS treatment is almost
entirely dependent on the activity of mPGES-1 [42]. Thus,
blockade of mPGES-1 expression by resveratrol is an addi-
tional effect of this compound that contributes to its
potent ability to block PGE2 synthesis in microglia. Res-
veratrol effects on mPGES-1 expression seem to be inde-
pendent on its ability to reduce COX activity/PGE2
formation since other COX inhibitors were unable to
modify LPS-induced mPGES-1 upregulation in microglial
cells despite their potent inhibitory effects on PGE2 pro-
duction (Figs. 6 and 7).
To the best of our knowledge, the present study is the first
to document the ability of resveratrol to reduce mPGES-1
expression, as shown here in activated microglia. It is of
great relevance that resveratrol reduced mPGES-1, but not
COX-2 expression (Fig. 4). This suggests that LPS-induced
microglial expression of mPGES-1 proceeds through
molecular mechanisms which are different from the ones
involved in COX-2 induction, providing for the first time
evidence that the expression of mPGES-1 and COX-2 are
not always coupled as suggested by other authors [75,76].
It has been recently reported that resveratrol reduces COX-
2 expression in mouse BV-2 microglial cells through a
mechanism that possibly involves inhibition of NF-κB
activation [77]. Our present findings are not in line with
these previous observations. The reasons for these discrep-
ancies are not known, but might be related to different cell
types and species (mouse BV-2 versus primary rat micro-
glia).
At this point we have not yet identified the exact signal
transduction pathway involved in resveratrol's effects on
mPGES-1 expression. However, present findings will
inspire new investigations in order to elucidate the differ-
ential signal transduction pathways responsible for the
expression of mPGES-1 and COX-2 in microglia. This is of
importance since this could lead to the discovery of new
targets for attenuating microglial activation and PGE2 syn-
thesis.
Because of the downstream position of mPGES-1 in the
PGE2-synthesizing cascade, selective pharmacological
blockade of its expression, as shown here for resveratrol,
would affect only the pro-inflammatory PGE2, and would
not decrease the production of other physiologically
important prostanoids. Although COX-2 inhibitors have
been highly marketed in the last five years including clin-
ical trials in Alzheimer's disease, there are also important
side effects associated with this new group of drugs
[78,79]. Thus, it is of paramount importance our finding
that resveratrol specifically reduced mPGES-1 without
affecting COX-2 levels. Recent evidence indicates that
enhanced expression and activity of mPGES-1 is a critical
pathological event during inflammation, both in the CNS
A: Effects of the antioxidant Trolox C and the COX-1 inhib- itors (SC-560 and VAS) on the expression of COX-1, COX- 2, and mPGES-1 mRNAs in rat microglial cells stimulated  with LPS Figure 7
A: Effects of the antioxidant Trolox C and the COX-1 inhib-
itors (SC-560 and VAS) on the expression of COX-1, COX-
2, and mPGES-1 mRNAs in rat microglial cells stimulated 
with LPS. RT-PCR analysis was performed after 4 h of incu-
bation with LPS. There are no significant effects of the COX-
1 inhibitors on mPGES-1 expression as demonstrated by the 
semi-quantitative analysis shown in Panel B. Trolox C pro-
duced a moderate reduction in mPGES-1 expression that did 
not attain statistical significance. Semi-quantitative analysis 
was done with results from 3 different RT-PCR experiments 
performed independently. Relative expression of rat S12 was 
used for normalization.
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and in the periphery. Mice lacking the mPGES-1 gene are
protected against stroke-induced injury [80] and display
reduced pain hypersensitivity and inflammation [81,82].
Conclusion
In summary, we are proposing here that significant atten-
uation of PGE2 and free radical production by activated
microglia might contribute to the neuroprotective effects
of resveratrol. This study gives further support to the
potential use of resveratrol as a therapeutic agent to
reduce microglial activation following different types of
brain injury.
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